Alpha 2.0
Login Register
» Authors » Monica Dickerson

Monica Dickerson

Explore the profile of Monica Dickerson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 1555
Followers 0
Related Specialties
Infectious Diseases
General Medicine
General Surgery
Top 10 Co-Authors
Allison L Naleway
Manjusha Gaglani
Toan C Ong
Julie Arndorfer
Shaun J Grannis
Stephanie A Irving
Malini B DeSilva
Kristin Dascomb
Palak Patel
Bruce Fireman
Published In
MMWR Morb Mortal Wkly Rep
J Infect Dis
Clin Infect Dis
Influenza Other Respir Viruses
JAMA Netw Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States
Tenforde M, Reeves E, Weber Z, Tartof S, Klein N, Dascomb K, et al.
Clin Infect Dis . 2024 Dec; PMID: 39656838
Background: The 2023-2024 influenza season had predominant influenza A(H1N1)pdm09 virus activity, but A(H3N2) and B viruses co-circulated. Seasonal influenza vaccine strains were well-matched to these viruses. Methods: Using health care...
2.
Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023
Tenforde M, Weber Z, Yang D, DeSilva M, Dascomb K, Irving S, et al.
J Infect Dis . 2024 Jul; 230(1):141-151. PMID: 39052725
Background: The 2022-2023 United States influenza season had unusually early influenza activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, with lower levels of A(H1N1)pdm09 activity also observed. Methods: Using...
3.
Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders
Levy M, Yang D, Dunne M, Miley K, Irving S, Grannis S, et al.
Influenza Other Respir Viruses . 2024 Mar; 18(3):e13269. PMID: 38494192
Background: Although psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID-19 vaccine effectiveness (VE). This study evaluated risk of COVID-19...
4.
Vaccine Effectiveness Against SARS-CoV-2 Related Hospitalizations in People who had Experienced Homelessness or Incarceration - Findings from the Minnesota EHR Consortium
DeSilva M, Knowlton G, Rai N, Bodurtha P, Essien I, Riddles J, et al.
J Community Health . 2023 Dec; 49(3):448-457. PMID: 38066221
COVID-19 disproportionately affects people experiencing homelessness or incarceration. While homelessness or incarceration alone may not impact vaccine effectiveness, medical comorbidities along with social conditions associated with homelessness or incarceration may...
5.
Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023
Griggs E, Mitchell P, Lazariu V, Gaglani M, McEvoy C, Klein N, et al.
Clin Infect Dis . 2023 Aug; 78(2):338-348. PMID: 37633258
Background: The epidemiology of coronavirus disease 2019 (COVID-19) continues to develop with emerging variants, expanding population-level immunity, and advances in clinical care. We describe changes in the clinical epidemiology of...
6.
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023
Link-Gelles R, Weber Z, Reese S, Payne A, Gaglani M, Adams K, et al.
Am J Transplant . 2023 Jul; 23(7):1062-1076. PMID: 37394267
No abstract available.
7.
Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study
Adams K, Riddles J, Rowley E, Grannis S, Gaglani M, Fireman B, et al.
Lancet Reg Health Am . 2023 Jun; 23:100530. PMID: 37333688
Background: Understanding the usefulness of additional COVID-19 vaccine doses-particularly given varying disease incidence-is needed to support public health policy. We characterize the benefits of COVID-19 booster doses using number needed...
8.
Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023
Link-Gelles R, Weber Z, Reese S, Payne A, Gaglani M, Adams K, et al.
MMWR Morb Mortal Wkly Rep . 2023 May; 72(21):579-588. PMID: 37227984
On September 1, 2022, CDC's Advisory Committee on Immunization Practices (ACIP) recommended a single bivalent mRNA COVID-19 booster dose for persons aged ≥12 years who had completed at least a...
9.
Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents
Klein N, Demarco M, Fleming-Dutra K, Stockwell M, Kharbanda A, Gaglani M, et al.
Pediatrics . 2023 Apr; 151(5). PMID: 37026401
Objectives: We assessed BNT162b2 vaccine effectiveness (VE) against mild to moderate and severe coronavirus disease 2019 (COVID-19) in children and adolescents through the Omicron BA.4/BA.5 period. Methods: Using VISION Network...
10.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022
Tenforde M, Weber Z, Natarajan K, Klein N, Kharbanda A, Stenehjem E, et al.
MMWR Morb Mortal Wkly Rep . 2023 Mar; 71(53):1637-1646. PMID: 36921274
During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of the sequenced viral genomes in the United States, with further Omicron sublineage diversification through November 2022.* Bivalent mRNA...